close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BioPorto A/S

News headline image
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
From BioPorto A/S
Via GlobeNewswire
News headline image
US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker
From BioPorto A/S
Via GlobeNewswire
News headline image
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences
From BioPorto A/S
Via GlobeNewswire
News headline image
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
From BioPorto A/S
Via GlobeNewswire
News headline image
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
From BioPorto A/S
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today